These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28228479)

  • 21. Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution.
    Lim SR; Qin X; Susser S; Nicholas JB; Lange C; Herrmann E; Hong J; Arfsten A; Hooi L; Bradford W; Nájera I; Smith P; Zeuzem S; Kossen K; Sarrazin C; Seiwert SD
    Antimicrob Agents Chemother; 2012 Jan; 56(1):271-9. PubMed ID: 22064535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of the NS5B S282T resistant variant and two novel amino acid substitutions that affect replication capacity in hepatitis C virus-infected patients treated with mericitabine and danoprevir.
    Tong X; Li L; Haines K; Najera I
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3105-14. PubMed ID: 24637689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry.
    Hinrichsen H; Stoehr A; Cornberg M; Klinker H; Heyne R; John C; Simon KG; Guenther V; Martin K; Witte V; Zeuzem S
    Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):415-423. PubMed ID: 32345848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance.
    Jensen SB; Serre SB; Humes DG; Ramirez S; Li YP; Bukh J; Gottwein JM
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7426-36. PubMed ID: 26392503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir.
    Berger KL; Sarrazin C; Nelson DR; Scherer J; Sha N; Marquis M; Côté-Martin A; Vinisko R; Stern JO; Mensa FJ; Kukolj G
    PLoS One; 2016; 11(8):e0160668. PubMed ID: 27494410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches.
    Ezat AA; Elshemey WM
    Life Sci; 2019 Jan; 217():176-184. PubMed ID: 30528183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.
    Lenz O; Verbinnen T; Fevery B; Tambuyzer L; Vijgen L; Peeters M; Buelens A; Ceulemans H; Beumont M; Picchio G; De Meyer S
    J Hepatol; 2015 May; 62(5):1008-14. PubMed ID: 25445400
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study.
    Boonma T; Nutho B; Darai N; Rungrotmongkol T; Nunthaboot N
    J Biomol Struct Dyn; 2022 Aug; 40(12):5283-5294. PubMed ID: 33430709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.
    Kileng H; Kjellin M; Akaberi D; Bergfors A; Duberg AS; Wesslén L; Danielsson A; Gangsøy Kristiansen M; Gutteberg T; Goll R; Lannergård A; Lennerstrand J
    Scand J Gastroenterol; 2018; 53(10-11):1347-1353. PubMed ID: 30394152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants.
    Summa V; Ludmerer SW; McCauley JA; Fandozzi C; Burlein C; Claudio G; Coleman PJ; Dimuzio JM; Ferrara M; Di Filippo M; Gates AT; Graham DJ; Harper S; Hazuda DJ; Huang Q; McHale C; Monteagudo E; Pucci V; Rowley M; Rudd MT; Soriano A; Stahlhut MW; Vacca JP; Olsen DB; Liverton NJ; Carroll SS
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4161-7. PubMed ID: 22615282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy.
    Miao M; Jing X; De Clercq E; Li G
    Drug Des Devel Ther; 2020; 14():2759-2774. PubMed ID: 32764876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in São Paulo state.
    Moreira RC; de Torres Santos AP; Lisboa-Neto G; Mendes-Corrêa MCJ; Lemos MF; Malta FM; Santana RAF; Dastoli GTF; de Castro VFD; Pinho JRR
    Arch Virol; 2018 Oct; 163(10):2757-2764. PubMed ID: 29961118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacophore-Assisted Covalent Docking Identifies a Potential Covalent Inhibitor for Drug-Resistant Genotype 3 Variants of Hepatitis C Viral NS3/4A Serine Protease.
    Iman K; Mirza MU; Sadia F; Froeyen M; Trant JF; Chaudhary SU
    Viruses; 2024 Aug; 16(8):. PubMed ID: 39205224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Avoiding Drug Resistance by Substrate Envelope-Guided Design: Toward Potent and Robust HCV NS3/4A Protease Inhibitors.
    Matthew AN; Zephyr J; Nageswara Rao D; Henes M; Kamran W; Kosovrasti K; Hedger AK; Lockbaum GJ; Timm J; Ali A; Kurt Yilmaz N; Schiffer CA
    mBio; 2020 Mar; 11(2):. PubMed ID: 32234812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.
    Serre SB; Jensen SB; Ghanem L; Humes DG; Ramirez S; Li YP; Krarup H; Bukh J; Gottwein JM
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3563-78. PubMed ID: 27021330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study.
    Fevery B; Verbinnen T; Peeters M; Janssen K; Witek J; Jessner W; De Meyer S; Lenz O
    J Viral Hepat; 2017 Jan; 24(1):28-36. PubMed ID: 27696653
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elbasvir/Grazoprevir: First Global Approval.
    Keating GM
    Drugs; 2016 Apr; 76(5):617-24. PubMed ID: 26943930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability.
    Dultz G; Srikakulam SK; Konetschnik M; Shimakami T; Doncheva NT; Dietz J; Sarrazin C; Biondi RM; Zeuzem S; Tampé R; Kalinina OV; Welsch C
    J Biol Chem; 2021 Sep; 297(3):101031. PubMed ID: 34339738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of the Q80K Polymorphism on the Physicochemical Properties of Hepatitis C Virus Subtype 1a NS3 Protease.
    Peres-da-Silva A; Antunes D; Quintanilha Torres AL; Caffarena ER; Lampe E
    Viruses; 2019 Jul; 11(8):. PubMed ID: 31366046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.